Kornimate/medical-research-clean huggingface dataset:
assessment of asthma mimics among newly diagnosed bronchial asthma patients

Conditions: Asthma (Diagnosis)

Summary: the aim of the study was to identify the percentage of patients in whom the diagnosis of current asthma was confirmed or ruled out after clinical, spirometric assessment and utilizing all the possible investigations with a six month follow up period for both groups.

the diagnosis of bronchial asthma relies on the existence of characteristic respiratory symptoms which are reversible and variable (diurnal and seasonal) with variable airflow limitation. unfortunately, bronchial asthma may mimic different pulmonary and non-pulmonary diseases regarding their similar clinical presentations so accurate assessment is required to exclude other possible diagnosis before confirming the diagnosis of bronchial asthma. there are various phenotypes of asthma as; atopic, non-atopic, and late-onset asthma, which may not be easily diagnosed in the community. also, asthma may show intermittent versus a relapsing /remitting course, so it is difficult to be diagnosed by a single physician visit. different studies have found that patients with bronchial asthma were treated empirically without full assessment either to ensure or exclude the asthma diagnosis. some symptoms as chest wheezes and breathlessness may be presented commonly in bronchial asthma and other mimic diseases as; chronic obstructive pulmonary disease, bronchiectasis, congestive heart failure, vocal cord disorders, hypersensitivity pneumonitis, endobronchial tumours, pulmonary embolism, aspiration syndromes, tracheal compression by a mediastinal mass and tracheomalacia. so, different physicians should put in mind those asthma mimics to be differentiated from asthmatic patients specially whose asthma symptoms are poorly controlled by anti- asthmatic medications.

Eligibility criteria:
inclusion criteria: * 1) patients aged ≥ 18 years who had newly clinically diagnosed bronchial asthma (the diagnosis was achieved in the previous one year, to allow us to get the previous diagnostic reports) whether the diagnosis of asthma was initially made based on clinical assessment alone or both clinical and spirometric assessment. 2) both sexes were included. exclusion criteria: * 1) patients who were using long-term oral steroids that may mask the diagnosis; 2) unable to do spirometry or contra-indicated. 3) pregnancy. 4) definite diagnosis of other chest diseases.

Keywords: asthma, mimic diseases, spirometry
effects of hydrotherapy in pain and quality of sleep's cycles in preterm newborn on neonatal intensive care units

Conditions: Perinatal Care

Summary: researchers suggest that the protection of the cycles of sleep is essential for neurodevelopment, learning, memory and preservation of brain plasticity to the individual's life. recent research shows that technical bath promote reduction of crying, anxiety and improves the behavior of newborns.

this was a pilot study assessing the technique in this population. the study was conducted with 8 stable premature infants admitted in the neonatal intensive care unit (icu) from hospital luterano de porto alegre. physiological and behavioral parameters were assessed by brazelton's neonatal behavior assessment scale, and the pain was evaluated by nfcs scale. the mean of brazelton's scale was reduced after the procedures from 5,88 ± 0.35 to 1,38 ± 0.74, p \< 0.001. the score in pain assessment scale was reduced from 5,38 ± 0.91 to 0.25 ± 0.46, p \< 0.001 after intervention. the study suggests that aquatic physical therapy could be a simple and effective method to reduce pain and stress in premature infants admitted in the neonatal icu.

Eligibility criteria:
inclusion criteria: * premature infants with gestational age less than 36 weeks, * clinically stable, showing behavioral abnormalities such as intolerance to the touch, excessive crying, showing signs of pain in accordance with the scale * difficulty of nfcs leave the stage of crying and agitation for a period of deep sleep during a period of not less than 60 minutes. exclusion criteria: * premature medically unstable because of the difficulty of monitoring in liquid medium, with a change in temperature on mechanical ventilation who had an infectious process due to the exacerbation of it in hot water, and syndromic children with congenital facial deformities that impede the use of scale nfcs for evaluation.

Keywords: hydrotherapy perinatal care neonatology
a multicenter, active and placebo-controlled study of enteric coated sevelamer in patients with mild to moderate hypercholesteremia

Conditions: Hypercholesterolemia

Summary: a total of 120 patients will be entered in this study to assess the safety and efficacy of enteric coated sevelamer (ecs) to lower ldl cholesterol. patients will be randomized into two active treatment groups, two placebo groups and one active control group.

this is a prospective, randomized, single blind, active and placebo-controlled, parallel-group, multi-center study. two groups of ecs consisting of 3 and 6 tablets/day (n=30), two placebo groups of 3 and 6 tablets/day (n=15 each) and one active control group of colesevelam 6 tablets/day (n=30). the study is being conducted solely in india and there will be a total of 6-8 sites. the safety parameters are: * serious adverse events saes * treatment and non-treatment emergent aes * physical exams and vital signs * clinical safety laboratories the efficacy parameters include a fasting lipid profile: * low density lipoproteins (ldl) * total cholesterol * high density lipoproteins (hdl) * triglycerides

Eligibility criteria:
inclusion criteria: * males and females 18 years of age or older * clinical diagnosis of mild to moderate hypercholesterolemia 1)ldl cholesterol greater than or equal to 130 mg/dl and less than or equal to 220 mg/dl 2) triglycerides less than or equal to 300 mg/dl exclusion criteria: * women who are pregnant or lactating. * patients using other lipid-lowering medications during . * patients with unstable medical conditions and/or comorbidities

Keywords: hypercholesterolemia, bile acid sequestrant, ldl-cholesterol
third molars extraction and periodontal disease

Conditions: Periodontal Diseases

Summary: the aim of the study is to evaluate the changes in periodontal conditions on the distal aspect of the second maxillary molar after the extraction of the maxillary wisdom tooth. as secondary outcome patient- related and tooth-related factors will be analysed to evaluate their effects on the periodontal varibales during time.


Eligibility criteria:
inclusion criteria: * age more than 18 years or older * presence of an impacted upper wisdom tooth that need to undergo surgical extraction * participants need to be able to sign and understand the informed consent and to follow the study-related procedures. exclusion criteria: * people that have compromised general health conditions (asa 3, 4, 5, 6) * patients that assumed antibiotics in the last 6 months * pregnant or breastfeeding women * patients who suffer from periodontitis stage iii and iv * presence of a third molar with incomplete root formation is not taken into account for the surgical extraction. * smoker patients
prospective comparison of incidence of heavy menstrual bleeding in women treated with direct oral anticoagulants

Conditions: Heavy Menstrual Bleeding

Summary: prospective comparison of the incidence of heavy menstrual bleeding (hmb) in women of reproductive age treated with direct oral anticoagulants (doacs)

patients will be treated as standard of care, no randomization schedule, no blinded investigational product (ip). the decision which doac will be given is made before the subject will enter the trial. the doac has to be taken at least for seven days. the registry is non-interventional (nis) with routine blood draw at baseline and at month 4 after inclusion. the prospective follow up will be up to four months. three consecutive menstrual bleeding cycles will be documented by the participating patients at home. one baseline data reporting and one follow up reporting after four months are planned in the participating coagulation centers. the primary aim is the comparison of the frequency of heavy menstrual bleeding in female patients of reproductive age anticoagulated with doacs using a modified pictorial blood loss assessment chart. secondary aims are the prevalence of von willebrand disease in young anticoagulated female patients and correlation of hmb with age, international society of thrombosis and hemostasis bleeding assessment tool at inclusion, blood group, anatomical reasons i.e. underlying uterine pathologies, i. e. presence of uterine fibroids, endometrial polyps and/or adenomyosis, occurrence of iron deficiency, hemoglobin level and intermittent use of non-steroidal anti-inflammatory drug (nsaid).

Eligibility criteria:
inclusion criteria: * women with venous thromboembolism * age: 18 - 50 years * regular menstrual bleeding * treatment with doacs for at least 7 days before inclusion * full therapeutic anticoagulation with rivaroxaban 1 x 20 mg, apixaban 2 x 5 mg, edoxaban 60mg once daily or dabigatran 2 x 150mg for at least the next four months * written informed consent exclusion criteria: * hysterectomy or ovariectomy * known heavy menstrual bleeding * hormonal contraceptives * hormone replacement therapy * use of hormone releasing intrauterine system (ius) * contraindications to treatment with doacs * treatment with rivaroxaban 15 mg twice daily (first three weeks after diagnosis of venous thrombosis) or apixaban 10 mg twice daily (first week after diagnosis of venous thrombosis) * treatment with rivaroxaban (10 mg or 15 mg once daily) or apixaban (2,5 mg twice daily) in reduced therapeutic dosages * participation in any other trial
eliminating risk of preventable adverse drug events at the hospital-community interface of care

Conditions: Adverse Drug Events

Summary: this initiative aims to decrease the risk of medication errors at the hospital-community interface as well as health system utilization following hospital discharge by implementing a pharmacist-led medication reconciliation in the patients' home within 72 hours of hospital discharge.

the goals of this initiative are to decrease the risk for medication errors at the hospital community interface of care, thus decreasing preventable adverse drug events and preventable drug-related health system utilization following hospital discharge. this initiative has four objectives that aim to: 1. develop and test a community-based medication reconciliation process/intervention. 2. design and conduct a randomized controlled trial to examine the impact of the intervention on post-discharge health services utilization by comparing a set of outcome variables between intervention and non-intervention groups. 3. design a risk prediction model that helps identify patients discharged from in-patient care with the highest level of need for the intervention. 4. determine whether a community-based medication reconciliation process/intervention adds risk reduction value to individuals who have undergone an in-hospital medication reconciliation.

Eligibility criteria:
inclusion criteria: * patients attending the westview health centre medicine/family health unit with at least one medication at discharge. exclusion criteria: * first nations persons * residents of continuing care or assisted living facilities * persons not residing in the edmonton, ab, canada region * persons who obtain a score of 19 or less on the mini mental state examination (mmse)

Keywords: adverse drug events medication reconciliation pharmacist-led intervention
the efficacy of neuromuscular electrical stimulation to attenuate muscle loss

Conditions: Muscle Disuse; Neuromuscular Electrical Stimulation (NMES); Critical Illness

Summary: subjects who are hospitalized in the icu will be included after 24 hours of intubation during their icu stay. twice-daily neuromuscular electrical stimulation (nmes) will be performed on one leg for 2x40 min per day to assess muscle fiber size. the investigators hypothesize an attenuated loss in muscle fiber size.


Eligibility criteria:
inclusion criteria: * male * age between 18 and 80 years * expected sedated time of \>24h exclusion criteria: * spinal cord injury * arterial operaties on the legs * local wounds that prohibit nmes * chronic use of corticosteroids * intake of certain antithrombotic drugs * presence of implantable cardioverter defibrillator and/or pacemaker
power-assisted therapeutic electrical stimulation to upper extremities

Conditions: Stroke

Summary: power-assisted therapeutic electrical stimulation (tes) or conventional tes to upper extremities in acute stroke patients were performed in a randomized controlled trial. the changes in finger and hand function will be evaluated. the hypothesis is that a power-assisted tes is more effective than a conventional tes.


Eligibility criteria:
inclusion criteria: * acute or subacute phase of stroke exclusion criteria: * chronic phase of stroke
prevention of seroma following inguinal lymph node dissection with prophylactic incisional negative pressure wound therapy

Conditions: Seroma; Surgical Site Infection; Lymphedema; Quality of Life

Summary: inguinal lymph node dissection (ilnd) is indicated following metastatic malignant melanoma, and is associated with a high-complication rate, of which many begin with the formation of seroma and ends in complicated wound healing, reoperation, multiple outpatient visits and re-hospitalization. prevention of seroma may therefore lead to a reduction of many of the preceding complications and improve patient quality-of-life. the aim of this study is to evaluate the efficacy and oncological safety of prophylactic negative pressure wound therapy following ilnd in melanoma patients.


Eligibility criteria:
inclusion criteria: * all malignant melanoma patients who are candidates for ilnd and 18 years of age or older exclusion criteria: * patients suspected of having tumor residuals after ilnd, previous groin irradiation or patients suffering from dementia or any psychiatric disorder making them incapable of informed consent or adherence to follow up, along with patients who are unable to communicate in danish or english will not be included in the study.
gut microbiota in patients with limb lymphedema and recurrent lymphangitis

Conditions: Lymphedema; Microbiota

Summary: lymphedema is a chronic and progressive disease of the lymphatic vessels which affects about 300 million people worldwide. patients may experience recurrent soft tissue infection of the limb affected by lymphedema, in terms of erysipelas, lymphangitis or cellulitis. no previous study has ever investigated the possible role of the gut microbiota in the genesis of acute infectious/inflammatory episodes in these patients. our hypothesis is that lymphedema patients with recurrent soft tissue infections are characterized by pro-inflammatory changes in the microbiota.


Eligibility criteria:
inclusion criteria (group a): * 18-85 years * primary or secondary, upper or lower limb lymphedema, i-ii-iii stage isl * at least 3 episodes of soft tissue infection in an year, in the last 2 years * consent to participate in the study inclusion criteria (group b): * 18-85 years * primary or secondary, upper or lower limb lymphedema, stage i-ii-iii (isl) * no episodes of soft tissue infection in the last 2 years * consent to participate in the study exclusion criteria: * no compliance to perform limb compression and skin hygiene * antibiotic therapy in the last 15 days * diabetes mellitus * immunodeficiency * ongoing neoplastic pathology * taking immunosuppressive drugs * unavailability to follow-up for at least 24 months post-enrollment.
future patient - telerehabilitation of atrial fibrillation patients

Conditions: Atrial Fibrillation

Summary: the idea behind this future patient pilot study is to explore and evaluate the feasibility of individualized telerehabilitation technologies and programs for patients with atrial fibrillation (af).

objective: to explore the feasibility of individualized telerehabilitation technologies and a program for patients with af. outcome measures: to evaluate two concepts for telerehabilitation programs and technologies for patients with af in order to see how these concepts can increase self-management for patients in their rehabilitation process. the following outcome measures are in focus: primary outcomes: * usability of technologies seen from patients' and healthcare professionals' perspectives * test and evaluation of the contents of telerehabilitation programs secondary outcomes: * measurements of clinical data * patients' and relatives' expectations for and experience with participation in the telerehabilitation program * healthcare professionals' experience with workflows and collaboration between each other in the telerehabilitation program

Eligibility criteria:
inclusion criteria: * patients diagnosed with af * adults ≥ 18 years; no upper age limit * patients living in skive and viborg municipality * living at home and capable of caring for him/herself * basic computer skills or a relative with basic computer skills exclusion criteria: * pregnancy * lack of ability to cooperate * patient does not speak, read and understand danish
picso in patients with stemi treated by primary percutaneous coronary intervention

Conditions: ST Elevation (STEMI) Myocardial Infarction

Summary: a prospective multi-center study in which patients with an acute heart attack (in the left anterior descending artery) with ecg changes (st segment elevation) receive angioplasty followed by stent placement and 90 minutes of picso treatment. this is a proof of concept study designed to document the safety and feasibility of the pressure controlled intermittent coronary sinus occlusion (picso) impulse system.


Eligibility criteria:
inclusion criteria: * first time anterior stemi defined by the following: * symptoms of myocardial ischemia \> 30 minutes and \< 12 hours * st-segment elevation \> 1mm (\> 0.1 mv) in two contiguous precordial leads in the anterior territory on a 12-lead ecg * uncomplicated pci of a lad culprit lesion (defined as angioplasty followed by stent placement or direct stenting without the occurrence of an adverse event(s) that would preclude further study participation, such as major bleeding, perforation, hypotension, pulmonary edema or instability that in the judgement of the investigator preclude participation in the trial) exclusion criteria: * younger than 18 years of age * hospitalization with a primary diagnosis of acute myocardial infarction (ami) previously or has evidence of previous q-wave infarct * left main coronary artery culprit lesion * additional stenosis in the lad for which pci or cabg is likely to be needed in the next 6 months and which is not treated during the index procedure * cardiogenic shock (systolic blood pressure ≤90 mmhg in spite of conservative measures) or pulmonary edema (o2 saturation \<90% by pulse oximetry and the presence of rales or crackles) * cardiac arrest requiring chest compression or resuscitation * anatomical complications limit capacity to place picso impulse device or achieve stable catheter placement or occlude coronary sinus * known renal disease (gfr \< 30 ml/min/1.73m2) or dialysis * history of stroke, tia or reversible ischemic neurological disease within last 6 months * left bundle branch block * known contra-indication for magnetic resonance imaging (metallic implant precluding mri, claustrophobia, obesity precluding mri, etc.) * presence of any lead in the coronary sinus * active or treated malignancies in the last 12 months * previous coronary artery bypass graft surgery * known severe anemia (hgb \< 10 g/dl or \< 6.2 mmol/l) * known platelet count \< 100,000, known coagulopathy or bleeding diathesis, or unwilling to accept transfusions * participation in another ongoing clinical study * women of child-bearing age * non-cardiac comorbidities and life expectancy \< 1 year * legal incompetence * a condition that, in the opinion of the investigator, precludes participation, including compliance with all follow-up procedures * no dependents neither to the sponsor nor to the investigator

Keywords: stemi picso coronary sinus involving left anterior descending coronary artery
iyengar yoga for chemotherapy-induced fatigue in breast cancer patients

Conditions: Breast Neoplasms; Fatigue

Summary: breast cancer is the most frequent cancer in women and is associated with profound restrictions of health-related quality of life and psychosocial health. more than three-quarters of women with breast cancer suffer from fatigue during cancer treatment. while exercise interventions can improve fatigue in breast cancer patients, many patients request complementary treatment approaches. therefore, this study investigates the effects of yoga in women with breast cancer compared to aerobic exercise and usual care. it is hypothesized that yoga is more effective than usual care and equally effective as aerobic exercise.


Eligibility criteria:
inclusion criteria: * non-metastatic invasive breast cancer * currently receiving adjuvant chemotherapy * moderate to severe chemotherapy-induced fatigue * physical and cognitive capacity to participate in yoga or walking exclusion criteria: * diagnosed and pharmacologically treated psychiatric disorder except depressive adaptation disorder as a reaction to cancer diagnosis * ecog status \> 1 * prior malignancy with a disease-free survival \< 10 years except curatively treated basalioma of the skin and carcinoma in situ of the cervix * prior ductal carcinoma in situ (dcis) ot the breast * pregnancy or breastfeeding * regular practice of yoga or walking during the past 12 months
"the effect of inhaled nitroglycerin for copd patients

Conditions: COPD; COPD III/IV

Summary: this study aims to investigative the benefits of using nebulized nitroglycerin in improving respiratory functions in patients of late stage copd

the inhaled nitroglycerin is expected to make vasodilatation of the pulmonary arteries and arterioles which are constricted in late stages of cobd leading to ventilation/perfusion mismatching and further aggravating copd. it will also help in delivering better antibiotic concentrations to the alveoli which help in better control of infection.

Eligibility criteria:
inclusion criteria: * adult patient's ≥ 18 years old copd exacerbation with respiratory failure and echo evidenced presence of pulmonary hypertension (defined as mean pulmonary artery pressure \> 20 mmhg) exclusion criteria: * profound left ventricular failure, as the decrease in pulmonary vascular resistance results in an increase in left ventricular preload. this may worsen cardiogenic pulmonary edema. * pregnant female patients * patient with hypersensitivity to nitroglycerin

Keywords: inhaled nitroglycerin